MYUNGMOON Pharm co.,Ltd

KOSE:A017180 Stock Report

Market Cap: ₩64.1b

MYUNGMOON PharmLtd Past Earnings Performance

Past criteria checks 0/6

MYUNGMOON PharmLtd has been growing earnings at an average annual rate of 42.4%, while the Pharmaceuticals industry saw earnings growing at 7.3% annually. Revenues have been growing at an average rate of 5.2% per year.

Key information

42.4%

Earnings growth rate

47.6%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate5.2%
Return on equity-9.7%
Net Margin-4.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Health Check: How Prudently Does MYUNGMOON PharmLtd (KRX:017180) Use Debt?

Dec 16
Health Check: How Prudently Does MYUNGMOON PharmLtd (KRX:017180) Use Debt?

Is MYUNGMOON PharmLtd (KRX:017180) Weighed On By Its Debt Load?

Sep 06
Is MYUNGMOON PharmLtd (KRX:017180) Weighed On By Its Debt Load?

MYUNGMOON Pharm co.,Ltd's (KRX:017180) 35% Share Price Surge Not Quite Adding Up

Jul 26
MYUNGMOON Pharm co.,Ltd's (KRX:017180) 35% Share Price Surge Not Quite Adding Up

MYUNGMOON PharmLtd (KRX:017180) Has No Shortage Of Debt

Mar 21
MYUNGMOON PharmLtd (KRX:017180) Has No Shortage Of Debt

Does MYUNGMOON PharmLtd (KRX:017180) Have A Healthy Balance Sheet?

Mar 31
Does MYUNGMOON PharmLtd (KRX:017180) Have A Healthy Balance Sheet?

Introducing MYUNGMOON PharmLtd (KRX:017180), A Stock That Climbed 77% In The Last Five Years

Feb 06
Introducing MYUNGMOON PharmLtd (KRX:017180), A Stock That Climbed 77% In The Last Five Years

Does Myungmoon Pharm (KRX:017180) Have A Healthy Balance Sheet?

Dec 15
Does Myungmoon Pharm (KRX:017180) Have A Healthy Balance Sheet?

Revenue & Expenses Breakdown

How MYUNGMOON PharmLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A017180 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24180,143-7,57498,3082,412
30 Jun 24176,368-7,71997,2002,648
31 Mar 24173,796-6,32293,3183,306
31 Dec 23169,567-4,52588,7792,970
30 Sep 23166,6984,14081,1902,686
30 Jun 23160,3665,17274,9892,450
31 Mar 23157,6387,48571,5481,952
31 Dec 22152,1357,86867,2021,711
30 Sep 22147,514-4,77072,9501,351
30 Jun 22145,836-4,99871,3801,530
31 Mar 22140,778-6,51765,9122,367
31 Dec 21137,760-6,86563,2392,065
30 Sep 21134,608-6,83061,0972,093
30 Jun 21131,560-11,50162,2141,600
31 Mar 21125,543-21,75167,788219
31 Dec 20127,853-27,63967,803535
30 Sep 20134,148-32,04270,770623
30 Jun 20141,691-28,65473,730623
31 Mar 20146,936-24,32573,789878
31 Dec 19149,346-20,40274,570676
30 Sep 19152,571-7,61266,886637
30 Jun 19147,467-6,68765,432637
31 Mar 19149,139-94562,783252
31 Dec 18147,49998861,369141
30 Sep 18142,3341,56962,7590
30 Jun 18142,4692,41461,9610
31 Mar 18142,6007,67263,0600
31 Dec 17140,1387,80763,1060
30 Sep 17139,5097,68861,8060
30 Jun 17141,9748,47162,3580
31 Mar 17140,9175,20659,1220
31 Dec 16142,1806,74658,7280
30 Sep 16138,775-9,11960,8995
30 Jun 16135,216-9,08558,2225
31 Mar 16130,907-13,35957,71019
31 Dec 15125,101-16,13557,25424
30 Sep 15121,032-87351,76719
30 Jun 15114,633-2,14749,56619
31 Mar 15108,93220146,1305
31 Dec 14105,42176144,0498
30 Sep 14101,79034642,27372
30 Jun 14100,1993341,23072
31 Mar 14101,35244341,60896

Quality Earnings: A017180 is currently unprofitable.

Growing Profit Margin: A017180 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A017180 is unprofitable, but has reduced losses over the past 5 years at a rate of 42.4% per year.

Accelerating Growth: Unable to compare A017180's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A017180 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.3%).

Return on Equity

High ROE: A017180 has a negative Return on Equity (-9.66%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 21:10
End of Day Share Price 2025/01/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MYUNGMOON Pharm co.,Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution